Rubfila International FY26 Financials and Strategic Divestment

Revenue: Rs 602.50 Cr | Profit After Tax: Rs 26.61 Cr

Reader Takeaway: Revenue growth is tempered by auditor concerns over contingency provisions and a non-arm's length divestment plan.

What just happened

Rubfila International released its 33rd Annual Report for FY 2025-26, showing revenue growth to Rs 602.50 crore from Rs 550.41 crore in the previous year. However, Profit After Tax declined to Rs 26.61 crore from Rs 29.44 crore. The Board has recommended a dividend of Rs 2.00 per share.

Why this matters

The company plans to sell its entire 100% stake in subsidiary Premier Tissues India to Finquest Personal Care for Rs 61 crore. While the management intends to focus on core operations, the transaction has been identified as non-arm's length. Additionally, statutory auditors issued a qualified opinion concerning a Rs 13.49 crore 'Provision for Contingencies,' stating it lacks sufficient justification under accounting standards.

What changes now

Shareholders will vote on the proposed dividend and the divestment of Premier Tissues India during the 33rd Annual General Meeting scheduled for September 29, 2026. The auditor's qualification regarding the contingency fund suggests potential further scrutiny by regulatory bodies regarding the company's accounting practices.

Governance updates

The board saw a change in leadership with the resignation of Mr. Bharat J. Dattani on July 16, 2026. Subsequently, Mr. Hardik B. Patel was appointed to the CSR Committee on August 11, 2026.

What to track next

Investors should monitor the outcome of the Special Resolution regarding the subsidiary sale and the company's future justification for its contingency provisions to address auditor concerns.